<DOC>
	<DOC>NCT02762136</DOC>
	<brief_summary>Functional dyspepsia (FD), which is one of the most common gastrointestinal disorders with high disease burden. Postprandial distress syndrome (PDS) is a common subtype of FD. Although the effectiveness of Chinese herbal formula of Xiang-sha-liu-jun granule (XSLJG) for alleviating PDS symptoms has been assessed in previous studies, more convinced evidence of randomized placebo-controlled study is needed.</brief_summary>
	<brief_title>Traditional Chinese Medicine Xiang-sha-liu-jun Granules in Patients With Postprandial Distress Syndrome(PDS)</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<criteria>i)Aging between 18 and 75 years, able to read and write Chinese; ii)have a TCM diagnosis of spleen deficiency and qi stagnation pattern; iii) Having normal esophagogastroduodenoscopy results within 6 months; iv) Having normal liver and renal function confirmed by blood tests within 3 months; v) Being diagnosed as PDS of FD by a specialist consultation; vi）Receiving no other treatments during the study; vii）Voluntarily agreeing with the study protocol and signing a written informed consent. i)Having peptic ulcer or gastroesophageal reflux disease confirmed by esophagogastroduodenoscopy; ii) Having obvious signs of irritable bowel syndrome; iii) Having alarm symptoms (weight loss, black or tar stool, or dysphagia); iv) Having serious structural disease (disease of heart, lung, liver or kidney) or mental illness; v) Having had surgery related with the gastrointestinal tract, except for appendectomy more than six months ago; vi) Pregnant or breastfeeding; vii) Being taking drugs which may affect the gastrointestinal tract; a minimum washout period of two weeks is required before participating in the trial; viii) Having a problem of malabsorption or maldigestion; ix) Having a history of allergies to the studied drugs and food; x) Having difficulties in attending the trial (such as paralysis, serious mental illness, dementia, renal diseases, stroke, coronary atherosclerotic heart diseases, diabetes or mental diseases, illiteracy); xi) Unwilling to sign the informed consent.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>